Liver fibrosis: a balance of ACEs?
- 2 July 2007
- journal article
- review article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 113 (3), 109-118
- https://doi.org/10.1042/cs20070026
Abstract
There is an increasing body of evidence to suggest that the RAS (renin–angiotensin system) contributes to tissue injury and fibrosis in chronic liver disease. A number of studies have shown that components of a local hepatic RAS are up-regulated in fibrotic livers of humans and in experimental animal models. Angiotensin II, the main physiological effector molecule of this system, mediates liver fibrosis by stimulating fibroblast proliferation (myofibroblast and hepatic stellate cells), infiltration of inflammatory cells, and the release of inflammatory cytokines and growth factors such as TGF (transforming growth factor)-β1, IL (interleukin)-1β, MCP (monocyte chemoattractant protein)-1 and connective tissue growth factor. Furthermore, blockade of the RAS by ACE (angiotensin-converting enzyme) inhibitors and angiotensin type 1 receptor antagonists significantly attenuate liver fibrosis in experimental models of chronic liver injury. In 2000 ACE2 (angiotensin-converting enzyme 2), a human homologue of ACE, was identified. ACE2 efficiently degrades angiotensin II to angiotensin-(1–7), a peptide which has recently been shown to have both vasodilatory and tissue protective effects. This suggests that ACE2 and its products may be part of an alternate enzymatic pathway in the RAS, which counterbalances the generation and actions of angiotensin II, the ACE2–angiotensin-(1–7)–Mas axis. This review focuses on the potential roles of the RAS, angiotensin II and ACE2 in chronic liver injury and fibrogenesis.Keywords
This publication has 96 references indexed in Scilit:
- CARMA3/Bcl10/MALT1-dependent NF-κB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- Circulating Activities of Angiotensin-Converting Enzyme, Its Homolog, Angiotensin-Converting Enzyme 2, and Neprilysin in a Family StudyHypertension, 2006
- Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosisBiochemical and Biophysical Research Communications, 2006
- PGE2 alleviates kidney and liver damage, decreases plasma renin activity and acute phase response in cirrhotic rats with acute liver damageExperimental and Toxicologic Pathology, 2005
- Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis CThe Esophagus, 2005
- N-Domain–Specific Substrate and C-Domain Inhibitors of Angiotensin-Converting EnzymeHypertension, 1998
- Angiotensin-(1-7) Inhibits Vascular Smooth Muscle Cell GrowthHypertension, 1996
- Transcription factors modulating angiotensinogen gene expression in hepatocytesKidney International, 1994
- Assessment of the renin-angiotensin system in cirrhotic patients: Comparison between plasma renin activity and direct measurement of immunoreactive reninJournal of Hepatology, 1992
- Diagnostic Significance of Serum Angiotensin-Converting Enzyme Activity in Biochemical Tests with Special Reference to Chronic Liver Diseases.Japanese Journal of Medicine, 1991